{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T00:59:15Z","timestamp":1785200355974,"version":"3.55.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T00:00:00Z","timestamp":1753660800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T00:00:00Z","timestamp":1753660800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100005006","name":"Asan Institute for Life Sciences, Asan Medical Center","doi-asserted-by":"publisher","award":["2022IP0065"],"award-info":[{"award-number":["2022IP0065"]}],"id":[{"id":"10.13039\/501100005006","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Gastric Cancer"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1007\/s10120-025-01648-0","type":"journal-article","created":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T07:06:34Z","timestamp":1753686394000},"page":"1158-1169","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Predictive value of homologous recombination-related gene mutations in survival outcomes of first-line nivolumab plus chemotherapy for gastric cancer"],"prefix":"10.1007","volume":"28","author":[{"given":"Yuna","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyung-Don","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sun Young","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyungeun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaewon","family":"Hyung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meesun","family":"Moon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinho","family":"Shin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young Soo","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tae Won","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1033-1263","authenticated-orcid":false,"given":"Min-Hee","family":"Ryu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,28]]},"reference":[{"key":"1648_CR1","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209\u201349.","journal-title":"CA Cancer J Clin"},{"key":"1648_CR2","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/S0140-6736(10)61121-X","volume":"376","author":"YJ Bang","year":"2010","unstructured":"Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376:687\u201397.","journal-title":"Lancet"},{"key":"1648_CR3","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.1016\/S0140-6736(23)02033-0","volume":"402","author":"YY Janjigian","year":"2023","unstructured":"Janjigian YY, Kawazoe A, Bai Y, Xu J, Lonardi S, Metges JP, et al. Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial. Lancet. 2023;402:2197\u2013208.","journal-title":"Lancet"},{"key":"1648_CR4","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S0140-6736(21)00797-2","volume":"398","author":"YY Janjigian","year":"2021","unstructured":"Janjigian YY, Shitara K, Moehler M, Garrido M, Salman P, Shen L, et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet. 2021;398:27\u201340.","journal-title":"Lancet"},{"key":"1648_CR5","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1016\/S1470-2045(23)00515-6","volume":"24","author":"SY Rha","year":"2023","unstructured":"Rha SY, Oh DY, Ya\u00f1ez P, Bai Y, Ryu MH, Lee J, et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol. 2023;24:1181\u201395.","journal-title":"Lancet Oncol"},{"key":"1648_CR6","doi-asserted-by":"publisher","first-page":"2064","DOI":"10.1001\/jama.2023.19918","volume":"330","author":"J Xu","year":"2023","unstructured":"Xu J, Jiang H, Pan Y, Gu K, Cang S, Han L, et al. sintilimab plus chemotherapy for unresectable gastric or gastroesophageal junction cancer: the ORIENT-16 randomized clinical trial. JAMA. 2023;330:2064\u201374.","journal-title":"JAMA"},{"key":"1648_CR7","doi-asserted-by":"publisher","first-page":"e078876","DOI":"10.1136\/bmj-2023-078876","volume":"385","author":"MZ Qiu","year":"2024","unstructured":"Qiu MZ, Oh DY, Kato K, Arkenau T, Tabernero J, Correa MC, et al. Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first line treatment for advanced gastric or gastro-oesophageal junction adenocarcinoma: RATIONALE-305 randomised, double blind, phase 3 trial. BMJ. 2024;385:e078876.","journal-title":"BMJ"},{"key":"1648_CR8","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1001\/jamaoncol.2021.0275","volume":"7","author":"J Chao","year":"2021","unstructured":"Chao J, Fuchs CS, Shitara K, Tabernero J, Muro K, Van Cutsem E, et al. Assessment of pembrolizumab therapy for the treatment of microsatellite instability-high gastric or gastroesophageal junction cancer among patients in the KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 clinical trials. JAMA Oncol. 2021;7:895\u2013902.","journal-title":"JAMA Oncol"},{"key":"1648_CR9","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1038\/s41591-018-0101-z","volume":"24","author":"ST Kim","year":"2018","unstructured":"Kim ST, Cristescu R, Bass AJ, Kim KM, Odegaard JI, Kim K, et al. Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer. Nat Med. 2018;24:1449\u201358.","journal-title":"Nat Med."},{"key":"1648_CR10","doi-asserted-by":"publisher","first-page":"e004080","DOI":"10.1136\/jitc-2021-004080","volume":"10","author":"Y Bai","year":"2022","unstructured":"Bai Y, Xie T, Wang Z, Tong S, Zhao X, Zhao F, et al. Efficacy and predictive biomarkers of immunotherapy in Epstein-Barr virus-associated gastric cancer. J Immunother Cancer. 2022;10:e004080.","journal-title":"J Immunother Cancer"},{"key":"1648_CR11","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1038\/s41591-025-03575-0","volume":"31","author":"K Shitara","year":"2025","unstructured":"Shitara K, Janjigian YY, Ajani J, Moehler M, Yao J, Wang X, et al. Nivolumab plus chemotherapy or ipilimumab in gastroesophageal cancer: exploratory biomarker analyses of a randomized phase 3 trial. Nat Med. 2025;31:1519\u201330.","journal-title":"Nat Med"},{"key":"1648_CR12","doi-asserted-by":"publisher","first-page":"CT023","DOI":"10.1158\/1538-7445.AM2022-CT023","volume":"82","author":"M Lei","year":"2022","unstructured":"Lei M, Janjigian YY, Ajani JA, Moehler M, Wang X, Shen L, et al. Abstract CT023 Nivolumab (NIVO) plus chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer\/gastroesophageal junction cancer\/esophageal adenocarcinoma (GC\/GEJC\/EAC) CheckMate 649 biomarker analyses. Cancer Res. 2022;82:CT023\u2013CT023.","journal-title":"Cancer Res"},{"key":"1648_CR13","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1038\/s41571-018-0114-z","volume":"16","author":"PG Pili\u00e9","year":"2019","unstructured":"Pili\u00e9 PG, Tang C, Mills GB, Yap TA. State-of-the-art strategies for targeting the DNA damage response in cancer. Nat Rev Clin Oncol. 2019;16:81\u2013104.","journal-title":"Nat Rev Clin Oncol"},{"key":"1648_CR14","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1038\/s41416-023-02326-7","volume":"129","author":"D Bhamidipati","year":"2023","unstructured":"Bhamidipati D, Haro-Silerio JI, Yap TA, Ngoi N. PARP inhibitors: enhancing efficacy through rational combinations. Br J Cancer. 2023;129:904\u201316.","journal-title":"Br J Cancer"},{"key":"1648_CR15","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1093\/annonc\/mdz192","volume":"30","author":"J Mateo","year":"2019","unstructured":"Mateo J, Lord CJ, Serra V, Tutt A, Balma\u00f1a J, Castroviejo-Bermejo M, et al. A decade of clinical development of PARP inhibitors in perspective. Ann Oncol. 2019;30:1437\u201347.","journal-title":"Ann Oncol"},{"key":"1648_CR16","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.ygyno.2019.02.011","volume":"153","author":"CB Morse","year":"2019","unstructured":"Morse CB, Toukatly MN, Kilgore MR, Agnew KJ, Bernards SS, Norquist BM, et al. Tumor infiltrating lymphocytes and homologous recombination deficiency are independently associated with improved survival in ovarian carcinoma. Gynecol Oncol. 2019;153:217\u201322.","journal-title":"Gynecol Oncol"},{"key":"1648_CR17","doi-asserted-by":"publisher","first-page":"1842","DOI":"10.1111\/1759-7714.15408","volume":"15","author":"A Gao","year":"2024","unstructured":"Gao A, Wang X, Wang J, Zhong D, Zhang L. Homologous recombination deficiency status predicts response to immunotherapy-based treatment in non-small cell lung cancer patients. Thorac Cancer. 2024;15:1842\u201353.","journal-title":"Thorac Cancer"},{"key":"1648_CR18","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.20892\/j.issn.2095-3941.2020.0351","volume":"18","author":"Z Gong","year":"2021","unstructured":"Gong Z, Yang Y, Zhang J, Guo W. Evaluation of 30 DNA damage response and 6 mismatch repair gene mutations as biomarkers for immunotherapy outcomes across multiple solid tumor types. Cancer Biol Med. 2021;18:1080\u201391.","journal-title":"Cancer Biol Med"},{"key":"1648_CR19","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1002\/mc.23562","volume":"62","author":"Y Lin","year":"2023","unstructured":"Lin Y, Luo S, Luo M, Lu X, Li Q, Xie M, et al. Homologous recombination repair gene mutations in colorectal cancer favors treatment of immune checkpoint inhibitors. Mol Carcinog. 2023;62:1271\u201383.","journal-title":"Mol Carcinog"},{"key":"1648_CR20","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1007\/s13577-021-00630-z","volume":"35","author":"C Yang","year":"2022","unstructured":"Yang C, Zhang Z, Tang X, Zhang X, Chen Y, Hu T, et al. Pan-cancer analysis reveals homologous recombination deficiency score as a predictive marker for immunotherapy responders. Hum Cell. 2022;35:199\u2013213.","journal-title":"Hum Cell"},{"key":"1648_CR21","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1007\/s10120-021-01233-1","volume":"25","author":"HD Kim","year":"2022","unstructured":"Kim HD, Ryu MH, Park YS, Lee SY, Moon M, Kang YK. Insertion-deletion rate is a qualitative aspect of the tumor mutation burden associated with the clinical outcomes of gastric cancer patients treated with nivolumab. Gastric Cancer. 2022;25:226\u201334.","journal-title":"Gastric Cancer"},{"key":"1648_CR22","doi-asserted-by":"publisher","first-page":"e108","DOI":"10.1093\/nar\/gkw227","volume":"44","author":"Z Lai","year":"2016","unstructured":"Lai Z, Markovets A, Ahdesmaki M, Chapman B, Hofmann O, McEwen R, et al. VarDict: a novel and versatile variant caller for next-generation sequencing in cancer research. Nucleic Acids Res. 2016;44:e108.","journal-title":"Nucleic Acids Res"},{"key":"1648_CR23","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1007\/s10120-024-01542-1","volume":"27","author":"H Ichikawa","year":"2024","unstructured":"Ichikawa H, Aizawa M, Kano Y, Hanyu T, Muneoka Y, Hiroi S, et al. Landscape of homologous recombination deficiency in gastric cancer and clinical implications for first-line chemotherapy. Gastric Cancer. 2024;27:1273\u201386.","journal-title":"Gastric Cancer"},{"key":"1648_CR24","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1038\/s41698-023-00442-4","volume":"7","author":"D Wang","year":"2023","unstructured":"Wang D, Elenbaas B, Murugesan K, Shah K, Montesion M, Gounaris I, et al. Relationship among DDR gene mutations, TMB and PD-L1 in solid tumour genomes identified using clinically actionable biomarker assays. NPJ Precis Oncol. 2023;7:103.","journal-title":"NPJ Precis Oncol"},{"key":"1648_CR25","doi-asserted-by":"publisher","first-page":"1327894","DOI":"10.3389\/fgene.2024.1327894","volume":"15","author":"M Boujemaa","year":"2024","unstructured":"Boujemaa M, Nouira F, Jandoubi N, Mejri N, Bouaziz H, Charfeddine C, et al. Uncovering the clinical relevance of unclassified variants in DNA repair genes: a focus on BRCA negative Tunisian cancer families. Front Genet. 2024;15:1327894.","journal-title":"Front Genet"},{"key":"1648_CR26","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1038\/s12276-024-01288-x","volume":"56","author":"R Kim","year":"2024","unstructured":"Kim R, Kim S, Oh BB, Yu WS, Kim CW, Hur H, et al. Clinical application of whole-genome sequencing of solid tumors for precision oncology. Exp Mol Med. 2024;56:1856\u201368.","journal-title":"Exp Mol Med"},{"key":"1648_CR27","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1007\/s10120-024-01500-x","volume":"27","author":"HD Kim","year":"2024","unstructured":"Kim HD, Shin J, Song IH, Hyung J, Lee H, Ryu MH, et al. Discordant PD-L1 results between 28\u20138 and 22C3 assays are associated with outcomes of gastric cancer patients treated with nivolumab plus chemotherapy. Gastric Cancer. 2024;27:819\u201326.","journal-title":"Gastric Cancer"},{"key":"1648_CR28","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.20892\/j.issn.2095-3941.2020.0089","volume":"17","author":"Y Fan","year":"2020","unstructured":"Fan Y, Ying H, Wu X, Chen H, Hu Y, Zhang H, et al. The mutational pattern of homologous recombination (HR)-associated genes and its relevance to the immunotherapeutic response in gastric cancer. Cancer Biol Med. 2020;17:1002\u201313.","journal-title":"Cancer Biol Med"},{"key":"1648_CR29","doi-asserted-by":"publisher","first-page":"22370","DOI":"10.1002\/cam4.6725","volume":"12","author":"J Chen","year":"2023","unstructured":"Chen J, Tang Y, Liu H, Sun G, Liu H, Zhao J, et al. The mutational pattern of homologous recombination repair genes in urothelial carcinoma and its correlation with immunotherapeutic response. Cancer Med. 2023;12:22370\u201380.","journal-title":"Cancer Med"},{"key":"1648_CR30","doi-asserted-by":"publisher","first-page":"3489","DOI":"10.1158\/1078-0432.CCR-22-0121","volume":"28","author":"KW Lee","year":"2022","unstructured":"Lee KW, Van Cutsem E, Bang YJ, Fuchs CS, Kudaba I, Garrido M, et al. Association of tumor mutational burden with efficacy of pembrolizumab\u00b1chemotherapy as first-line therapy for gastric cancer in the phase III KEYNOTE-062 Study. Clin Cancer Res. 2022;28:3489\u201398.","journal-title":"Clin Cancer Res"},{"key":"1648_CR31","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1038\/s41597-023-02331-8","volume":"10","author":"A Farmanbar","year":"2023","unstructured":"Farmanbar A, Kneller R, Firouzi S. Mutational signatures reveal mutual exclusivity of homologous recombination and mismatch repair deficiencies in colorectal and stomach tumors. Sci Data. 2023;10:423.","journal-title":"Sci Data"},{"key":"1648_CR32","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1158\/1535-7163.MCT-20-0879","volume":"21","author":"M Cerniglia","year":"2022","unstructured":"Cerniglia M, Xiu J, Grothey A, Pishvaian MJ, Baca Y, Hwang JJ, et al. Association of homologous recombination-dna damage response gene mutations with immune biomarkers in gastroesophageal cancers. Mol Cancer Ther. 2022;21:227\u201336.","journal-title":"Mol Cancer Ther"},{"key":"1648_CR33","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1038\/s41698-024-00672-0","volume":"8","author":"L Incorvaia","year":"2024","unstructured":"Incorvaia L, Bazan Russo TD, Gristina V, Perez A, Brando C, Mujacic C, et al. The intersection of homologous recombination (HR) and mismatch repair (MMR) pathways in DNA repair-defective tumors. NPJ Precis Oncol. 2024;8:190.","journal-title":"NPJ Precis Oncol"},{"key":"1648_CR34","doi-asserted-by":"publisher","first-page":"5584","DOI":"10.1093\/nar\/gkad308","volume":"51","author":"JM Oh","year":"2023","unstructured":"Oh JM, Kang Y, Park J, Sung Y, Kim D, Seo Y, et al. MSH2-MSH3 promotes DNA end resection during homologous recombination and blocks polymerase theta-mediated end-joining through interaction with SMARCAD1 and EXO1. Nucleic Acids Res. 2023;51:5584\u2013602.","journal-title":"Nucleic Acids Res"},{"key":"1648_CR35","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.ccell.2020.11.004","volume":"39","author":"J Guan","year":"2021","unstructured":"Guan J, Lu C, Jin Q, Lu H, Chen X, Tian L, et al. MLH1 deficiency-triggered DNA hyperexcision by exonuclease 1 activates the cGAS-STING pathway. Cancer Cell. 2021;39:109\u201321.","journal-title":"Cancer Cell"},{"key":"1648_CR36","doi-asserted-by":"publisher","first-page":"13587","DOI":"10.18632\/oncotarget.7277","volume":"7","author":"KC Strickland","year":"2016","unstructured":"Strickland KC, Howitt BE, Shukla SA, Rodig S, Ritterhouse LL, Liu JF, et al. Association and prognostic significance of BRCA1\/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1\/PD-L1 in high grade serous ovarian cancer. Oncotarget. 2016;7:13587\u201398.","journal-title":"Oncotarget"},{"key":"1648_CR37","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1038\/nature13954","volume":"515","author":"PC Tumeh","year":"2014","unstructured":"Tumeh PC, Harview CL, Yearley JH, Shintaku IP, Taylor EJ, Robert L, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature. 2014;515:568\u201371.","journal-title":"Nature"},{"key":"1648_CR38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41523-023-00609-z","volume":"10","author":"M Chen","year":"2024","unstructured":"Chen M, Yu S, van der Sluis T, Zwager MC, Schr\u00f6der CP, van der Vegt B, et al. cGAS-STING pathway expression correlates with genomic instability and immune cell infiltration in breast cancer. NPJ Breast Cancer. 2024;10:1.","journal-title":"NPJ Breast Cancer"},{"key":"1648_CR39","doi-asserted-by":"publisher","first-page":"323","DOI":"10.4132\/jptm.2023.10.22","volume":"57","author":"JH Oh","year":"2023","unstructured":"Oh JH, Sung CO, Kim HD, Chun SM, Kim J. BRCA-mutated gastric adenocarcinomas are associated with chromosomal instability and responsiveness to platinum-based chemotherapy. J Pathol Transl Med. 2023;57:323\u201331.","journal-title":"J Pathol Transl Med"},{"key":"1648_CR40","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.1158\/0008-5472.CAN-22-2620","volume":"83","author":"A Petrelli","year":"2023","unstructured":"Petrelli A, Rizzolio S, Pietrantonio F, Bellomo SE, Benelli M, De Cecco L, et al. BRCA2 germline mutations identify gastric cancers responsive to PARP inhibitors. Cancer Res. 2023;83:1699\u2013710.","journal-title":"Cancer Res"},{"key":"1648_CR41","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1038\/s41698-024-00561-6","volume":"8","author":"A Prosz","year":"2024","unstructured":"Prosz A, Sahgal P, Huffman BM, Sztupinszki Z, Morris CX, Chen D, et al. Mutational signature-based identification of DNA repair deficient gastroesophageal adenocarcinomas for therapeutic targeting. NPJ Precis Oncol. 2024;8:87.","journal-title":"NPJ Precis Oncol"},{"key":"1648_CR42","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s40364-025-00740-y","volume":"13","author":"A Witz","year":"2025","unstructured":"Witz A, Dardare J, Betz M, Michel C, Husson M, Gilson P, et al. Homologous recombination deficiency (HRD) testing landscape: clinical applications and technical validation for routine diagnostics. Biomark Res. 2025;13:31.","journal-title":"Biomark Res"},{"key":"1648_CR43","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1158\/1078-0432.CCR-23-2249","volume":"30","author":"Y Drew","year":"2024","unstructured":"Drew Y, Kim JW, Penson RT, O\u2019Malley DM, Parkinson C, Roxburgh P, et al. Olaparib plus Durvalumab, with or without Bevacizumab, as treatment in PARP inhibitor-na\u00efve platinum-sensitive relapsed ovarian cancer: a phase ii multi-cohort study. Clin Cancer Res. 2024;30:50\u201362.","journal-title":"Clin Cancer Res"},{"key":"1648_CR44","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1001\/jamaoncol.2019.1048","volume":"5","author":"PA Konstantinopoulos","year":"2019","unstructured":"Konstantinopoulos PA, Waggoner S, Vidal GA, Mita M, Moroney JW, Holloway R, et al. Single-arm phases 1 and 2 trial of niraparib in combination with pembrolizumab in patients with recurrent platinum-resistant ovarian carcinoma. JAMA Oncol. 2019;5:1141\u20139.","journal-title":"JAMA Oncol"},{"key":"1648_CR45","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1016\/S1470-2045(17)30682-4","volume":"18","author":"YJ Bang","year":"2017","unstructured":"Bang YJ, Xu RH, Chin K, Lee KW, Park SH, Rha SY, et al. Olaparib in combination with paclitaxel in patients with advanced gastric cancer who have progressed following first-line therapy (GOLD): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2017;18:1637\u201351.","journal-title":"Lancet Oncol"}],"container-title":["Gastric Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10120-025-01648-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10120-025-01648-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10120-025-01648-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T00:02:06Z","timestamp":1785196926000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10120-025-01648-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,28]]},"references-count":45,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["1648"],"URL":"https:\/\/doi.org\/10.1007\/s10120-025-01648-0","relation":{},"ISSN":["1436-3291","1436-3305"],"issn-type":[{"value":"1436-3291","type":"print"},{"value":"1436-3305","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,28]]},"assertion":[{"value":"18 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Nothing directly related to this work. Out of this work, MHR received honoraria from DAEHWA Pharmaceutical, Bristol Myers Squibb, Lilly, Ono Pharmaceutical, MSD, Taiho Pharmaceutical, Novartis, Daiichi Sankyo, and AstraZeneca, and served as a consultant for DAEHWA Pharmaceutical, Bristol Myers Squibb, Lilly and Ono Pharmaceutical. HDK received research grants from Roche\/Genentech, Amgen, and AstraZeneca and honoraria from AstraZeneca, Bristol Myers Squibb, Ono Pharmaceuticals, Boryung Pharmaceuticals, MSD, Daiichi Sankyo, Astellas, Boostimmune, DAEHWA Pharmaceutical, LG Chem, and MustBio. TWK received research grants from Genetech.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}